|
1
|
Peschon JJ, Morrissey PJ, Grabstein KH,
Ramsdell FJ, Maraskovsky E, Gliniak BC, Park LS, Ziegler SF,
Williams DE, Ware CB, et al: Early lymphocyte expansion is severely
impaired in interleukin 7 receptor-deficient mice. J Exp Med.
180:1955–1960. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
von Freeden-Jeffry U, Vieira P, Lucian LA,
McNeil T, Burdach SE and Murray R: Lymphopenia in interleukin
(IL)-7 gene-deleted mice identifies IL-7 as a nonredundant
cytokine. J Exp Med. 181:1519–1526. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Goetz CA, Harmon IR, O'Neil JJ, Burchill
MA and Farrar MA: STAT5 activation underlies IL7 receptor-dependent
B cell development. J Immunol. 172:4770–4778. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jiang Q, Li WQ, Aiello FB, Mazzucchelli R,
Asefa B, Khaled AR and Durum SK: Cell biology of IL-7, a key
lymphotrophin. Cytokine Growth Factor Rev. 16:513–533. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhang XM and Guo MZ: The value of
epigenetic markers in esophageal cancer. Front Med China.
4:378–384. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rustgi AK and El-Serag HB: Esophageal
carcinoma. N Engl J Med. 371:2499–2509. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pennathur A, Gibson MK, Jobe BA and
Luketich JD: Oesophageal carcinoma. Lancet. 381:400–412. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lin DC, Hao JJ, Nagata Y, Xu L, Shang L,
Meng X, Sato Y, Okuno Y, Varela AM, Ding LW, et al: Genomic and
molecular characterization of esophageal squamous cell carcinoma.
Nat Genet. 46:467–473. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Song Y, Li L, Ou Y, Gao Z, Li E, Li X,
Zhang W, Wang J, Xu L, Zhou Y, et al: Identification of genomic
alterations in oesophageal squamous cell cancer. Nature. 509:91–95.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
You JS and Han JH: Targeting components of
epigenome by small molecules. Arch Pharm Res. 37:1367–1374. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jones PA, Issa JP and Baylin S: Targeting
the cancer epigenome for therapy. Nat Rev Genet. 17:630–641. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ropero S and Esteller M: The role of
histone deacetylases (HDACs) in human cancer. Mol Oncol. 1:19–25.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li Y and Seto E: HDACs and HDAC inhibitors
in cancer development and therapy. Cold Spring Harb Perspect Med.
6:a0268312016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xu WS, Parmigiani RB and Marks PA: Histone
deacetylase inhibitors: Molecular mechanisms of action. Oncogene.
26:5541–5552. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Minucci S and Pelicci PG: Histone
deacetylase inhibitors and the promise of epigenetic (and more)
treatments for cancer. Nat Rev Cancer. 6:38–51. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
You JS, Kang JK, Lee EK, Lee JC, Lee SH,
Jeon YJ, Koh DH, Ahn SH, Seo DW, Lee HY, et al: Histone deacetylase
inhibitor apicidin downregulates DNA methyltransferase 1 expression
and induces repressive histone modifications via recruitment of
corepressor complex to promoter region in human cervix cancer
cells. Oncogene. 27:1376–1386. 2008. View Article : Google Scholar
|
|
17
|
Gu W and Roeder RG: Activation of p53
sequence-specific DNA binding by acetylation of the p53 C-terminal
domain. Cell. 90:595–606. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhao Y, Lu S, Wu L, Chai G, Wang H, Chen
Y, Sun J, Yu Y, Zhou W, Zheng Q, et al: Acetylation of p53 at
lysine 373/382 by the histone deacetylase inhibitor depsipeptide
induces expression of p21(Waf1/Cip1). Mol Cell Biol. 26:2782–2790.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Evsyukova I, Bradrick SS, Gregory SG and
Garcia-Blanco MA: Cleavage and polyadenylation specificity factor 1
(CPSF1) regulates alternative splicing of interleukin 7 receptor
(IL7R) exon 6. RNA. 19:103–115. 2013. View Article : Google Scholar :
|
|
20
|
Jung M: Inhibitors of histone deacetylase
as new anticancer agents. Curr Med Chem. 8:1505–1511. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Goto H, Tomono Y, Ajiro K, Kosako H,
Fujita M, Sakurai M, Okawa K, Iwamatsu A, Okigaki T, Takahashi T,
et al: Identification of a novel phosphorylation site on histone H3
coupled with mi-totic chromosome condensation. J Biol Chem.
274:25543–25549. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Prigent C and Dimitrov S: Phosphorylation
of serine 10 in histone H3, what for? J Cell Sci. 116:3677–3685.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kerdiles YM, Beisner DR, Tinoco R, Dejean
AS, Castrillon DH, DePinho RA and Hedrick SM: Foxo1 links homing
and survival of naive T cells by regulating L-selectin, CCR7 and
interleukin 7 receptor. Nat Immunol. 10:176–184. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Feng X, Wang H, Takata H, Day TJ, Willen J
and Hu H: Transcription factor Foxp1 exerts essential
cell-intrinsic regulation of the quiescence of naive T cells. Nat
Immunol. 12:544–550. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Goossens S, Radaelli E, Blanchet O,
Durinck K, Van der Meulen J, Peirs S, Taghon T, Tremblay CS, Costa
M, Farhang Ghahremani M, et al: ZEB2 drives immature T-cell
lympho-blastic leukaemia development via enhanced tumour-initiating
potential and IL-7 receptor sig-nalling. Nat Commun. 6:57942015.
View Article : Google Scholar
|
|
26
|
Omilusik KD, Best JA, Yu B, Goossens S,
Weidemann A, Nguyen JV, Seuntjens E, Stryjew-ska A, Zweier C,
Roychoudhuri R, et al: Transcriptional repressor ZEB2 promotes
terminal differen-tiation of CD8+ effector and memory T cell
populations during infection. J Exp Med. 212:2027–2039. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhong C, Cui K, Wilhelm C, Hu G, Mao K,
Belkaid Y, Zhao K and Zhu J: Group 3 innate lymphoid cells
continuously require the transcription factor GATA-3 after
commitment. Nat Im-munol. 17:169–178. 2016. View Article : Google Scholar
|
|
28
|
Daitoku H, Sakamaki J and Fukamizu A:
Regulation of FoxO transcription factors by acety-lation and
protein-protein interactions. Biochim Biophys Acta. 1813:1954–1960.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Garraway LA and Lander ES: Lessons from
the cancer genome. Cell. 153:17–37. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lawrence MS, Stojanov P, Mermel CH,
Robinson JT, Garraway LA, Golub TR, Meyerson M, Gabriel SB, Lander
ES and Getz G: Discovery and saturation analysis of cancer genes
across 21 tumour types. Nature. 505:495–501. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tran H, Brunet A, Griffith EC and
Greenberg ME: The many forks in FOXO's road. Sci STKE.
2003:RE52003.PubMed/NCBI
|
|
32
|
Accili D and Arden KC: FoxOs at the
crossroads of cellular metabolism, differentiation, and
transformation. Cell. 117:421–426. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Van Der Heide LP, Hoekman MF and Smidt MP:
The ins and outs of FoxO shuttling: Mechanisms of FoxO
translocation and transcriptional regulation. Biochem J.
380:297–309. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Barthel A, Schmoll D and Unterman TG: FoxO
proteins in insulin action and metabolism. Trends Endocrinol Metab.
16:183–189. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Calnan DR and Brunet A: The FoxO code.
Oncogene. 27:2276–2288. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Nasrin N, Ogg S, Cahill CM, Biggs W, Nui
S, Dore J, Calvo D, Shi Y, Ruvkun G and Alexan-der-Bridges MC:
DAF-16 recruits the CREB-binding protein coactivator complex to the
insulin-like growth factor binding protein 1 promoter in HepG2
cells. Proc Natl Acad Sci USA. 97:10412–10417. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Essers MA, Weijzen S, de Vries-Smits AM,
Saarloos I, de Ruiter ND, Bos JL and Burgering BM: FOXO
transcription factor activation by oxidative stress mediated by the
small GTPase Ral and JNK. EMBO J. 23:4802–4812. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Oh SW, Mukhopadhyay A, Svrzikapa N, Jiang
F, Davis RJ and Tissenbaum HA: JNK regu-lates lifespan in
Caenorhabditis elegans by modulating nuclear translocation of
forkhead tran-scription factor/DAF-16. Proc Natl Acad Sci USA.
102:4494–4499. 2005. View Article : Google Scholar
|
|
39
|
Lehtinen MK, Yuan Z, Boag PR, Yang Y,
Villén J, Becker EB, DiBacco S, de la Iglesia N, Gygi S, Blackwell
TK, et al: A conserved MST-FOXO signaling pathway mediates
oxidative-stress responses and extends life span. Cell.
125:987–1001. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kitamura YI, Kitamura T, Kruse JP, Raum
JC, Stein R, Gu W and Accili D: FoxO1 protects against pancreatic
beta cell failure through NeuroD and MafA induction. Cell Metab.
2:153–163. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Matsuzaki H, Daitoku H, Hatta M, Aoyama H,
Yoshimochi K and Fukamizu A: Acetylation of Foxo1 alters its
DNA-binding ability and sensitivity to phosphorylation. Proc Natl
Acad Sci USA. 102:11278–11283. 2005. View Article : Google Scholar : PubMed/NCBI
|
